CARMEL, Ind. – Syra Health Corp. (NASDAQ: SYRA), a healthcare technology company with a market capitalization of $8.5 million and showing strong recent momentum with a 19% gain over the past week, has been awarded a contract by the Washington D.C. government for up to $1 million to provide healthcare workforce solutions to the Office of the State Superintendent of Education. Additionally, the company announced an increase in its contract with the Indiana Family and Social Services Administration’s NeuroDiagnostic Institute by $1.2 million, now totaling $18.7 million. According to InvestingPro data, the company maintains a healthy balance sheet with more cash than debt, though analysts note rapid cash utilization.
The new contract with Washington D.C. involves Syra Health deploying registered nurses, licensed practical nurses, and certified nursing assistants to deliver healthcare services to students, ensuring their safety and well-being. The company will work within D.C. regulations and develop individualized service plans, with the one-year agreement allowing for potential extensions.
In Indiana, Syra Health’s expanded contract supports the NeuroDiagnostic Institute’s efforts to evaluate and treat patients with complex neuropsychiatric illnesses. Dr. Deepika Vuppalanchi, CEO of Syra Health, expressed the company’s commitment to driving better health outcomes through these partnerships, noting that this is the fourth contract with the Washington, D.C. government and a continuation of their collaboration with the NeuroDiagnostic Institute since 2021.
Syra Health specializes in behavioral and mental health, population health, and healthcare workforce solutions, leveraging advanced technology to improve prevention, access, and affordability in healthcare.
The press release also contained forward-looking statements about the company’s future plans and prospects, cautioning that these statements are subject to risks and uncertainties. Investors are reminded to consider the risk factors detailed in the company’s annual and periodic SEC filings. The information presented is based on the press release statement from Syra Health.
In other recent news, Syra Health Corp has been navigating potential delisting from the Nasdaq Stock Market due to non-compliance with the minimum bid price requirement. The company has been given a grace period until April 16, 2025, to ensure its common stock’s closing bid price reaches or exceeds $1.00 for at least ten consecutive business days. Additionally, Syra Health faces a potential delisting due to an equity shortfall and has a 45-day window to present a compliance plan to Nasdaq.
Despite these challenges, Syra Health continues to expand its footprint in the healthcare sector, securing contracts in Florida, Kansas, and Delaware, thereby marking its presence in 23 states. The company has also been awarded a $5.8 million contract by the Indiana Family and Social Services Administration and secured a contract with the Wyoming Department of Health.
In terms of financial developments, Syra Health has raised approximately $2.1 million in a public offering, with potential additional gross proceeds of $4.1 million from the exercise of Series Warrants, as per Rodman & Renshaw LLC. Furthermore, the company has updated its financial outlook for 2024, projecting revenues between $7.5 million and $9.5 million. These recent developments underline Syra Health’s ongoing efforts to navigate financial challenges while continuing to grow its business operations.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
